140 related articles for article (PubMed ID: 2149509)
1. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
de Voogt HJ; Klijn JG; Studer U; Schröder F; Sylvester R; De Pauw M
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):965-9. PubMed ID: 2149509
[TBL] [Abstract][Full Text] [Related]
2. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.
de Voogt HJ; Studer U; Schröder FH; Klijn JG; de Pauw M; Sylvester R
Eur Urol; 1998; 33(2):152-8. PubMed ID: 9519356
[TBL] [Abstract][Full Text] [Related]
3. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne FM
Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
[TBL] [Abstract][Full Text] [Related]
4. Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
Klijn JG; de Voogt HJ; Studer UE; Schröder FH; Sylvester R; De Pauw M
Cancer; 1993 Dec; 72(12 Suppl):3858-62. PubMed ID: 8252504
[TBL] [Abstract][Full Text] [Related]
5. Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
Bouffioux C
Eur Urol; 1988; 15(3-4):187-92. PubMed ID: 2975222
[TBL] [Abstract][Full Text] [Related]
6. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Sylvester RJ; Denis L; de Voogt H
Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
[TBL] [Abstract][Full Text] [Related]
7. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
Boccon-Gibod L; Laudat MH; Dugue MA; Steg A
Eur Urol; 1986; 12(6):400-2. PubMed ID: 2949980
[TBL] [Abstract][Full Text] [Related]
8. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ
J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
[TBL] [Abstract][Full Text] [Related]
9. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.
de Voogt HJ
Prostate Suppl; 1992; 4():91-5. PubMed ID: 1533452
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
Moffat LE
Eur Urol; 1990; 18 Suppl 3():26-7. PubMed ID: 2151272
[No Abstract] [Full Text] [Related]
11. Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
Denis L; Robinson M; Mahler C; Smith P; Keuppens F; De Moura JL; Bono A; Newling D; Sylvester R; De Pauw M
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):951-9. PubMed ID: 2149508
[TBL] [Abstract][Full Text] [Related]
12. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
Di Silverio F; Sciarra F; D'Eramo G
Eur Urol; 1990; 18(1):10-5. PubMed ID: 2144819
[TBL] [Abstract][Full Text] [Related]
13. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Di Silverio F; Serio M; D'Eramo G; Sciarra F
Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
[TBL] [Abstract][Full Text] [Related]
14. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
Waxman J
Prog Clin Biol Res; 1989; 303():61-8. PubMed ID: 2528741
[No Abstract] [Full Text] [Related]
15. Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial.
Ostri P; Bonnesen T; Nilsson T; Frimodt-Møller C
Urol Int; 1991; 46(2):167-71. PubMed ID: 1711250
[TBL] [Abstract][Full Text] [Related]
16. Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate.
Robinson MR
Prog Clin Biol Res; 1987; 243A():383-90. PubMed ID: 2958863
[No Abstract] [Full Text] [Related]
17. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
[TBL] [Abstract][Full Text] [Related]
18. Use of cyproterone acetate in prostate cancer.
Goldenberg SL; Bruchovsky N
Urol Clin North Am; 1991 Feb; 18(1):111-22. PubMed ID: 1825143
[TBL] [Abstract][Full Text] [Related]
19. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
[No Abstract] [Full Text] [Related]
20. [Cyproterone acetate in the treatment of post-orchiectomy flushing].
Jansen JE; Hendriksen ON
Ugeskr Laeger; 1989 Feb; 151(9):560-1. PubMed ID: 2522257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
